Mankhwala a shuga amatha kusintha zizindikiro za matenda a Parkinson
Lixisenatide, glucagon-ngati peptide-1 receptor agonist (GLP-1RA) pochiza matenda a shuga, amachepetsa dyskinesia mwa odwala omwe ali ndi matenda a Parkinson oyambirira, malinga ndi zotsatira za kuyesa kwachipatala kwa gawo lachiwiri lofalitsidwa mu New England Journal of Medicine. NEJM) pa 4 Epulo 2024.
Kafukufukuyu, motsogozedwa ndi University Hospital of Toulouse (France), adalemba anthu 156, omwe amagawidwa mofanana pakati pa gulu la mankhwala a lixisenatide ndi gulu la placebo.Ofufuzawo anayeza zotsatira za mankhwalawa pogwiritsa ntchito chiwerengero cha Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPRSS) Gawo lachitatu, ndi kuchuluka kwapamwamba pamlingo wosonyeza kusokonezeka kwakukulu kwa kayendetsedwe kake.Zotsatira zinasonyeza kuti pa mwezi wa 12, chiwerengero cha MDS-UPDRS gawo III chinachepa ndi mfundo za 0.04 (zosonyeza kusintha pang'ono) mu gulu la lixisenatide ndikuwonjezeka ndi mfundo za 3.04 (zomwe zimasonyeza kuwonjezereka kwa matendawa) mu gulu la placebo.
Mkonzi wamakono wa NEJM adanenanso kuti, pamwamba, izi zikusonyeza kuti lixisenatide inalepheretsa kuwonjezereka kwa zizindikiro za matenda a Parkinson m'miyezi 12, koma izi zikhoza kukhala maganizo abwino kwambiri.Miyeso yonse ya MDS-UPDRS, kuphatikizapo Gawo III, ndi masikelo ophatikizika okhala ndi magawo ambiri, ndipo kusintha kwa gawo limodzi kumatha kuthana ndi kuwonongeka kwina.Kuonjezera apo, magulu onse a mayesero angakhale apindula pongotenga nawo mbali mu mayesero a zachipatala.Komabe, kusiyana pakati pa magulu awiriwa akuwoneka kuti ndi enieni, ndipo zotsatira zake zimathandizira zotsatira za lixisenatide pa zizindikiro za matenda a Parkinson ndi njira ya matenda omwe angakhalepo.
Pankhani ya chitetezo, 46 peresenti ya anthu omwe amathandizidwa ndi lixisenatide adachita nseru ndipo 13 peresenti adasanza. Mkonzi wa NEJM akusonyeza kuti zochitika za zotsatirapo zingalepheretse kufala kwa lixisenatide pochiza matenda a Parkinson, choncho kufufuza kwina kwa kuchepetsa mlingo ndi njira zina zothandizira zingakhale zothandiza.
"M'mayeserowa, kusiyana kwa chiwerengero cha MDS-UPDRS kunali kofunika kwambiri koma kochepa pambuyo pa miyezi ya 12 ya mankhwala ndi lixisenatide. Kufunika kwa kupeza kumeneku sikuli pa kukula kwa kusintha, koma zomwe zikuwonetseratu."Nkhani yomwe tatchulayi ikulemba kuti, "Chodetsa nkhaŵa kwambiri kwa odwala ambiri a Parkinson si momwe alili panopa, koma kuopa kuwonjezereka kwa matenda. Ngati lixisenatide imapangitsa kuti MDS-UPDRS ipitirire ndi mfundo zambiri za 3, ndiye kuti chithandizo chamankhwala cha mankhwala chikhoza kukhala chochepa. Komano, ngati mphamvu ya lixisenatide ikuchulukirachulukira, ndikuwonjezera mfundo zina za 3 pachaka pazaka 5 mpaka 10 kapena kuposerapo, ndiye kuti izi zitha kukhala zosintha zenizeni sitepe yotsatira ndikuyesa kuyesa kwa nthawi yayitali."
Yopangidwa ndi wopanga mankhwala waku France Sanofi (SNY.US), lixisenatide idavomerezedwa ndi US Food and Drug Administration (FDA) kuti azichiza matenda a shuga amtundu wa 2 mu 2016, zomwe zidapangitsa kuti ikhale yachisanu GLP-1RA kugulitsidwa padziko lonse lapansi. kuchokera ku mayesero azachipatala, sizothandiza kuchepetsa shuga monga momwe amachitira liraglutide ndi Exendin-4, ndipo kulowa kwake mumsika wa US kunabwera mochedwa kuposa awo, zomwe zimapangitsa kuti zikhale zovuta kuti mankhwalawa apezeke.Mu 2023, lixisenatide idachotsedwa pamsika waku US.Sanofi akufotokoza kuti izi zinali chifukwa cha malonda m'malo mwa chitetezo kapena zovuta za mankhwala.
Matenda a Parkinson ndi matenda a neurodegenerative omwe amapezeka makamaka pakati pa akuluakulu ndi akuluakulu, makamaka omwe amadziwika ndi kupuma, kugwedezeka komanso kuyenda pang'onopang'ono, ndi chifukwa chosadziwika.Pakalipano, chithandizo chachikulu cha matenda a Parkinson ndi dopaminergic replacement therapy, yomwe imagwira ntchito makamaka kuti ikhale ndi zizindikiro ndipo ilibe umboni wokhutiritsa wokhudza kukula kwa matenda.
Kafukufuku wambiri wam'mbuyomu adapeza kuti GLP-1 receptor agonists amachepetsa kutupa kwaubongo.Kutupa kwa Neuroinflammation kumabweretsa kutayika kwapang'onopang'ono kwa ma cell aubongo omwe amapanga dopamine, gawo lalikulu la matenda a Parkinson.Komabe, ma GLP-1 receptor agonists okha omwe ali ndi mwayi wopita ku ubongo ndi othandiza pa matenda a Parkinson, ndipo posachedwapa semaglutide ndi liraglutide, omwe amadziwika bwino chifukwa cha kuwonda kwawo, sanasonyeze kuti angathe kuchiza matenda a Parkinson.
M'mbuyomu, kafukufuku wochitidwa ndi gulu la ofufuza a Institute of Neurology ku yunivesite ya London (UK) adapeza kuti exenatide, yomwe imakhala yofanana ndi lixisenatide, imawongolera zizindikiro za matenda a Parkinson.Zotsatira za mayeserowa zinasonyeza kuti pa masabata a 60, odwala omwe amathandizidwa ndi exenatide anali ndi kuchepa kwa mfundo imodzi m'magulu awo a MDS-UPDRS, pamene omwe amathandizidwa ndi placebo anali ndi kusintha kwa mfundo za 2.1.Wopangidwa ndi Eli Lilly (LLY.US), kampani yayikulu yaku US yopanga zamankhwala, exenatide ndiye woyamba padziko lonse lapansi wa GLP-1 receptor agonist, yemwe adalamulira msika kwa zaka zisanu.
Malinga ndi ziwerengero, osachepera asanu ndi limodzi a GLP-1 receptor agonists adayesedwa kapena akuyesedwa pano kuti agwire bwino ntchito pochiza matenda a Parkinson.
Malinga ndi World Parkinson's Association, pali odwala matenda a Parkinson 5.7 miliyoni padziko lonse lapansi, ndipo pafupifupi 2.7 miliyoni ku China.Pofika chaka cha 2030, dziko la China lidzakhala ndi theka la anthu onse padziko lapansi a Parkinson.Msika wapadziko lonse wa mankhwala a Parkinson's disease udzakhala ndi malonda a RMB 38.2 biliyoni mu 2023 ndipo akuyembekezeka kufika RMB 61.24 biliyoni mu 2030, malinga ndi DIResaerch (DIResaerch).
Nthawi yotumiza: Apr-24-2024
.png)
